Literature DB >> 12707374

Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Kathleen M Murphy1, Mark Levis, Michael J Hafez, Tanya Geiger, Lisa C Cooper, B Douglas Smith, Donald Small, Karin D Berg.   

Abstract

FLT3 is a receptor tyrosine kinase that is expressed on early hematopoietic progenitor cells and plays an important role in stem cell survival and differentiation. Two different types of functionally important FLT3 mutations have been identified. Internal tandem duplication mutations arise from duplications of the juxtamembrane portion of the gene and result in constitutive activation of the FLT3 protein. This alteration has been identified in approximately 20% to 30% of patients with acute myelogenous leukemia and appears to be associated with a worse prognosis. The second type of FLT3 mutation, missense mutations at aspartic acid residue 835, occurs in approximately 7.0% of acute myelogenous leukemia cases. These mutations also appear to be activating and to portend a worse prognosis. Identification of FLT3 mutations is important because it provides prognostic information and may play a pivotal role in determining appropriate treatment options. We have developed an assay to identify both internal tandem duplication and D835 FLT3 mutations in a single multiplex polymerase chain reaction. After amplification, the polymerase chain reaction products are analyzed by capillary electrophoresis for length mutations and resistance to EcoRV digestion. Here we describe the performance characteristics of the assay, assay validation, and our clinical experience using this assay to analyze 147 clinical specimens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707374      PMCID: PMC1907323          DOI: 10.1016/S1525-1578(10)60458-8

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  23 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.

Authors:  F M Abu-Duhier; A C Goodeve; G A Wilson; R S Care; I R Peake; J T Reilly
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

3.  Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells.

Authors:  H J McKenna; K L Stocking; R E Miller; K Brasel; T De Smedt; E Maraskovsky; C R Maliszewski; D H Lynch; J Smith; B Pulendran; E R Roux; M Teepe; S D Lyman; J J Peschon
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

4.  Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.

Authors:  D L Stirewalt; C L Willman; J P Radich
Journal:  Leuk Res       Date:  2001-12       Impact factor: 3.156

5.  A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Authors:  M Levis; K F Tse; B D Smith; E Garrett; D Small
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

6.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Authors:  Y Yamamoto; H Kiyoi; Y Nakano; R Suzuki; Y Kodera; S Miyawaki; N Asou; K Kuriyama; F Yagasaki; C Shimazaki; H Akiyama; K Saito; M Nishimura; T Motoji; K Shinagawa; A Takeshita; H Saito; R Ueda; R Ohno; T Naoe
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

7.  Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene.

Authors:  Y Nakano; H Kiyoi; S Miyawaki; N Asou; R Ohno; H Saito; T Naoe
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

8.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

9.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Authors:  Mark Levis; Jeffrey Allebach; Kam-Fai Tse; Rui Zheng; Brenda R Baldwin; B Douglas Smith; Susan Jones-Bolin; Bruce Ruggeri; Craig Dionne; Donald Small
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

10.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Authors:  S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

View more
  65 in total

1.  Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Authors:  Mark Levis; Farhad Ravandi; Eunice S Wang; Maria R Baer; Alexander Perl; Steven Coutre; Harry Erba; Robert K Stuart; Michele Baccarani; Larry D Cripe; Martin S Tallman; Giovanna Meloni; Lucy A Godley; Amelia A Langston; Sergio Amadori; Ian D Lewis; Arnon Nagler; Richard Stone; Karen Yee; Anjali Advani; Dan Douer; W Wiktor-Jedrzejczak; Gunnar Juliusson; Mark R Litzow; Stephen Petersdorf; Miguel Sanz; Hagop M Kantarjian; Takashi Sato; Lothar Tremmel; Debra M Bensen-Kennedy; Donald Small; B Douglas Smith
Journal:  Blood       Date:  2011-01-26       Impact factor: 22.113

2.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Authors:  Jorge Cortes; Alexander E Perl; Hartmut Döhner; Hagop Kantarjian; Giovanni Martinelli; Tibor Kovacsovics; Philippe Rousselot; Björn Steffen; Hervé Dombret; Elihu Estey; Stephen Strickland; Jessica K Altman; Claudia D Baldus; Alan Burnett; Alwin Krämer; Nigel Russell; Neil P Shah; Catherine C Smith; Eunice S Wang; Norbert Ifrah; Guy Gammon; Denise Trone; Deborah Lazzaretto; Mark Levis
Journal:  Lancet Oncol       Date:  2018-05-31       Impact factor: 41.316

3.  Δ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Roy G Rich; Michael J Hafez; Shuko Harada; Kathleen M Murphy; James R Eshleman; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

Review 4.  The Future of Targeting FLT3 Activation in AML.

Authors:  Mark B Leick; Mark J Levis
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

5.  Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Authors:  Syed M Kazmi; Naveen Pemmaraju; Keyur P Patel; Philip R Cohen; Naval Daver; Kathy M Tran; Farhad Ravandi; Madeleine Duvic; Guillermo Garcia-Manero; Sherry Pierce; Aziz Nazha; Gautam Borthakur; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-24

Review 6.  Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Authors:  Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith
Journal:  Leuk Res       Date:  2017-08-30       Impact factor: 3.156

7.  Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data.

Authors:  David H Spencer; Manoj Tyagi; Francesco Vallania; Andrew J Bredemeyer; John D Pfeifer; Rob D Mitra; Eric J Duncavage
Journal:  J Mol Diagn       Date:  2013-11-05       Impact factor: 5.568

8.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Authors:  Keith W Pratz; Takashi Sato; Kathleen M Murphy; Adam Stine; Trivikram Rajkhowa; Mark Levis
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

Review 9.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

10.  A robust xenotransplantation model for acute myeloid leukemia.

Authors:  P V Sanchez; R L Perry; J E Sarry; A E Perl; K Murphy; C R Swider; A Bagg; J K Choi; J A Biegel; G Danet-Desnoyers; M Carroll
Journal:  Leukemia       Date:  2009-07-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.